Pleural mesothelioma: lines of therapy

Cancer page →

5 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Screening, prevention and diagnosis	1
Advanced, first line	2
Second line	1
Other settings	1

Screening, prevention and diagnosis

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Diagnosis and staging	CT and PET-CT; thoracoscopic biopsy with an immunohistochemistry panel; histology and BAP1/MTAP status recorded because they drive treatment.	Mesothelioma		-

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	First line, non-epithelioid	Nivolumab plus ipilimumab (CheckMate 743).	NivolumabIpilimumabCheckMate 743		98
All comers	First line, epithelioid	Pembrolizumab with platinum-pemetrexed (KEYNOTE-483), nivolumab plus ipilimumab, or platinum-pemetrexed with or without bevacizumab, by fitness and preference.	PembrolizumabPemetrexedIND.227 / KEYNOTE-483		98

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Second line	Nivolumab (CONFIRM) if not given first line; chemotherapy rechallenge or gemcitabine or vinorelbine after immunotherapy.	Nivolumab		98

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Surgery	Not recommended for cure outside trials after MARS 2; talc pleurodesis or an indwelling pleural catheter controls effusion.	MARS 2		53

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.